ENO2 and X-linked adrenoleukodystrophy: In this sense, we aimed to describe the symptomatic status of our X-ALD heterozygote cohort; to measure the neurological manifestations through myelopathy scales JOA and SSPROM, peripheral nerve conduction studies and somatosensory evoked responses; to measure plasma levels of a neuron disease marker, neuron-specific enolase (NSE); and to look for associations between these parameters and independent variables such as age, age at onset, mutations, X inactivation pattern and plasma VLCFA.